Johnson & Johnson Innovative Medicine Skip to content Discover J&J Medicines & therapies Medical devices & technology Discover J&J Medicines & therapies Medical devices & technology Careers Media Contact locationPlaceholder Choose your country or region Global Global English North America North America (Regional) English Canada English Français United States English Asia Pacific Asia Pacific (Regional) English Australia English China 中文 Hong Kong English 中文 Japan 日本 Korea 한국어 New Zealand English Europe, Middle East & Africa (EMEA) EMEA (Regional) English Middle East - Africa الشرق الأوسط و أفريقيا (عربي) Austria Deutsch Belgium English Français Netherlands Bulgaria БЪЛГАРСКИ Croatia Hrvatski Czech Republic čeština Denmark Dansk Estonia English Finland Suomi France Français Germany Deutsch Greece ΕΛΛΗΝΙΚΑ Hungary Magyar Ireland English Israel עברית Italy Italiano Latvia English Lithuania English Netherlands Netherlands Norway Norsk Poland Polski Portugal Português Romania Română Russia Pусский Serbia Srpski Slovakia Slovenčina Slovenia Slovenščina South Africa English Spain Español Switzerland Français Deutsch Sweden Svensk Turkey Türkçe United Kingdom English Latin America Latin America (Regional) Español Argentina Español Bolivia Español Brazil Português Central America and the Caribbean Español Chile Español Colombia Español Ecuador Español Mexico Español Paraguay Español Peru Español Uruguay Español Healthcare areas Oncology Immunology Neuroscience Cardiopulmonary Products Clinical trials Pipeline Patient resources Innovative Medicine healthcare areas Menu Healthcare areas Oncology Immunology Neuroscience Cardiopulmonary Products Clinical trials Pipeline Patient resources Careers Media Contact Show Search Search Query Clear Submit Search Dictate search request Listening... Search Results No Results See all results Sorry, I don't understand. Please try again December 29, 2025 Johnson & Johnson completes acquisition of Halda Therapeutics and its novel platform to revolutionize cancer treatment and enable next-generation oral therapies Acquisition brings an advanced, highly differentiated treatment for prostate cancer, strengthening Johnson & Johnson’s longstanding commitment to innovation in the disease. Lead asset demonstrates potential to overcome key resistance pathways in prostate cancer through targeted tumor cell eradication. Learn more Innovative Medicine December 17, 2025 U.S. FDA approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) enables the simplest, shortest administration time for a first-line combination regimen when combined with LAZCLUZE® (lazertinib) RYBREVANT FASPRO™, the first and only subcutaneous therapy for patients with EGFR-mutated NSCLC, reduces administration time from hours to minutes and significantly reduces administration-related reactions1-5 Approval builds on previously reported Phase 3 MARIPOSA data showing unmatched overall survival benefit of this chemotherapy-free regimen, projected to exceed four years6 Learn more Innovative Medicine November 6, 2025 FDA approval of CAPLYTA® (lumateperone) has the potential to reset treatment expectations, offering hope for remission in adults with major depressive disorder CAPLYTA®, in combination with an oral antidepressant, demonstrated superior efficacy with a favorable safety and tolerability profile consistent with established indications1,2 In pivotal trials, CAPLYTA® did not increase mean weight gain, metabolic changes, or reported sexual side effects1,2 In a six-month open-label extension safety study, safety profile was consistent with pivotal studies and 80% of MDD patients taking CAPLYTA® achieved response, with 65% of patients reaching remission from depression3 CAPLYTA® offers a new option for the 2 in 3 people who experience residual symptoms despite their current antidepressant treatment1,2,3 Learn more Innovative Medicine November 6, 2025 DARZALEX FASPRO® is the first and only treatment approved by the U.S. FDA for patients with high-risk smoldering multiple myeloma Phase 3 AQUILA study showed DARZALEX FASPRO® significantly reduced the risk of progression to active multiple myeloma or death by 51 percent compared to active monitoring Landmark approval supports earlier intervention and disease interception of multiple myeloma for the first time Learn more Areas of focus Our transformational medicines are developed with rigorous science and unwavering compassion to provide the greatest impact for patients. We create new and groundbreaking medicines to change the future of health. Our scientists and researchers are pioneering the path from lab to life and championing patients each step of the way. Oncology Learn more Immunology Learn more Neuroscience Learn more Cardiopulmonary Learn more At Johnson & Johnson, we are leading where medicine is going, with a relentless focus on bringing transformational medical innovation to patients who are waiting. Our team’s deep expertise and global reach are helping us reimagine how devastating diseases are treated and cured, delivering hope and better care for millions of patients and their families around the world. Jennifer L. Taubert Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson Prescribers & physicians Products A-Z Pipeline Clinical trial finder for healthcare professionals Innovation partners Innovation focus Partnership/innovation opportunities Patients & caregivers Patient resources J&J Clinical Trials Pre-approval process Investors Investor events Pipeline ESG Policies & Positions Job seekers Explore jobs Life at J&J How we hire Policymakers & media Contact us Media center Policy center Resources Partnerships | J&J Innovative Medicine Read more Patient resources July 10, 2025 J&J’s approach to pricing Read more Transparency Read more Our innovations Precision medicine Read more Discovery, product development & supply Read more Data science & digital health Read more Newsroom The latest news, information, and stories from Johnson & Johnson Innovative Medicine. See all news Additional links Clinical trials Read more Pre-approval access Read more Contact us Read more Back to top Discover J&J News Our Credo & our purpose Leadership Social impact Suppliers Our history Policies & reports Environmental sustainability Medicines & therapies Products Oncology Immunology Neuroscience Cardiopulmonary Medical devices & technologies Products Cardiovascular Orthopaedics Surgery Vision About us Our company Medicines & therapies Medical devices & technology Careers Investors Media Key links Privacy Legal Notice Cookie policy Customize cookie settings Get in touch Contact Socials linkedin instagram twitter facebook youtube Your use of information on this site is subject to the terms of our Legal Notice. Please see our Privacy Policy. This site is published by Johnson & Johnson and its affiliates, which is solely responsible for its contents. Capitalized product names are trademarks of Johnson & Johnson or its affiliated companies. This information is intended for a global audience. Information specific to individual markets is identified where it appears. All third-party trademarks used herein are registered trademarks of their respective owners. Last Updated: June 18, 2025. Do not sell or share my personal information Limit the use of my sensitive personal information © Johnson & Johnson and its affiliates, 2012-2025. All Rights Reserved.